Dare Bioscience vs Inhibrx Biosciences
Inhibrx Biosciences is the larger business, with $1.3m of revenue in fiscal 2025 against $1.0m for Dare Bioscience (1.3 times as much). Dare Bioscience grew faster (10429.4% against 550.0%). Dare Bioscience kept more of each dollar of sales as profit: a net margin of -1300.7% against -10773.5%. Dare Bioscience carries less debt relative to equity (0.0% against 1258.1%).
| Latest fiscal year | Dare BioscienceDARE, 2025 | Inhibrx BiosciencesINBX, 2025 |
|---|---|---|
| Revenue | $1.0m | $1.3m |
| Revenue growth | 10429.4% | 550.0% |
| Net income | −$13.4m | −$140m |
| Operating margin | -1315.5% | -10386.5% |
| Net margin | -1300.7% | -10773.5% |
| Return on equity | — | -197.8% |
| Free cash flow | −$10.3m | −$130m |
| Cash | $24.7m | $124m |
| Total debt | $0 | $101m |
| Debt to equity | 0.0% | 1258.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 24 | 110 |
| Market value | $9.7m | $1.21bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 19 buys, 5 sales |